glp 1 compound ending 🚨 FDA Moves to Permanently Shut Down Compounded GLP-1s The FDA is taking steps to eliminate large-scale compounding of GLP-1 medications like semaglutide and tirzepatide, signaling a major shift in how these Managing Compounded GLP-1 Medications: A

Contact your healthcare provider if you experience: Absent periods (amenorrhea): Missing three or more consecutive menstrual cycles if previously regular, or six or more months if previously irregular Heavy bleeding (menorrhagia): Soaking through a pad or tampon every hour for several consecutive hours, or periods lasting longer than seven days Severe pain: New or worsening menstrual cramping not relieved by over-the-counter medications Intermenstrual bleeding: Bleeding or spotting between periods that persists beyond initial treatment months Pregnancy possibility: Any missed period when pregnancy is possible, as tirzepatide is not recommended during pregnancy Urgent warning signs: Heavy bleeding with dizziness, fainting, rapid heartbeat, or severe weakness requires emergency evaluation Your healthcare provider may recommend specific investigations to evaluate persistent menstrual irregularities

All other GLP-1 medications, including Ozempic and Mounjaro, are currently FDA-indicated for people diagnosed with Type 2 diabetes

Figure 3 GJA or pouch conversion can be performed by either reshaping these structures or by removing part of the GJA followed by a reconstruction (87)

After an injury, the body releases TB4, which works to reduce inflammation and protect cells and tissues from further damage. The authors go on to explain that TB4s tissue regeneration ability is partially due to its promoting the formation of new blood vessels (angiogenesis)